20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency.

[1]  A N N Gardulf,et al.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease , 2015, Clinical and experimental immunology.

[2]  H. Kanegane,et al.  Erratum to: Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases , 2014, Journal of Clinical Immunology.

[3]  C. Landersdorfer,et al.  Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency , 2013, Postgraduate medicine.

[4]  Smita Y. Patel,et al.  Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor , 2013, Clinical and experimental immunology.

[5]  V. Wahn,et al.  Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. , 2011, Clinical immunology.

[6]  E. López-Granados,et al.  Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. , 2010, The Journal of allergy and clinical immunology.

[7]  S. Spector,et al.  Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency , 2010, Journal of Clinical Immunology.

[8]  V. Bonagura,et al.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. , 2008, The Journal of allergy and clinical immunology.